Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Grand View Research | PRODUCT CODE: 1233127

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1233127

Generic Pharmaceuticals Market Size, Share & Trends Analysis Report By Type (Simple Generics, Specialty Generics, Biosimilars), By Route Of Administration, By Product, By Application, By Distribution Channel, By Region & Segment Forecasts, 2023-2030

PUBLISHED:
PAGES: 220 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Generic Pharmaceuticals Market Growth & Trends:

The global generic pharmaceuticals market is expected to reach over USD 682.9 billion expanding at a CAGR of 8.3% from 2023 to 2030, according to a new study by Grand View Research, Inc. The growth of the generic pharmaceuticals market is largely attributable to the expiry of product patents which clears the way for generic drugs and biosimilar manufacturers to launch products in the market. For instance, in July 2020, Teva Pharmaceutical Industries Ltd. entered into a joint venture with Takeda Pharmaceutical Company Limited aimed to manufacture and commercialize specialty assets, complex generic drugs, and other pipeline opportunities. This joint venture was anticipated to drive the generic pharmaceuticals market.

Furthermore, increasing government initiatives to promote generic drug products for reducing the overall healthcare expenditure on pharmaceuticals and the patent expiry of major products. For instance, the Therapeutic Goods Administration (TGA) Australia aims to offer affordable, efficient, high-quality, and accessible generic drugs to citizens for their treatment. In support of generic drugs, the TGA has been trying to reduce regulatory and reimbursement burdens such as changing the landscape of generic drugs and reducing barriers through international collaboration with manufacturers to launch their generic drugs in the market. Such initiatives of the Australian government open new avenues in the market.

In the U.S., every year millions of Americans use a generic drug for their treatment, hence, generic drugs remain the best bargain in the health care insurance programs, and given the recent enactment of healthcare reform legislation such as the introduction of the Patient Protection and Affordable Health Care Act. P.L. 111-148. Under this act, prescription drug coverage is mandated by the government as part of these new health insurance plans. The introduction of such policies may improve the quality and efficiency of healthcare, thereby, driving market growth.

The rising disease burden of infectious & non-infectious diseases coupled with the increasing geriatric population which is prone to chronic diseases such as diabetes, and hypertension, among others, may positively affect the market growth. According to an article published, in September 2022, around 17.9 million general population suffer from cardiovascular diseases (CVD) every year worldwide. Diseases including TB, diabetes, cardiovascular diseases, and HIV were among the major causes of death. The increasing incidence and prevalence of these diseases is expected to drive the market.

Generic Pharmaceuticals Market Report Highlights:

  • The small molecule segment by type held the largest share of 91.2% in 2022 and the large molecule segment is expected to grow at the fastest rate. The increasing approval and uptake of biosimilars is expected to drive the growth of the large molecule segment.
  • Based on the route of administration, the injectable segment is the fastest-growing segment due to the rising approval for biosimilar drugs.
  • By application, cardiovascular diseases dominated the market with a share of 18.27% in 2022, owing to the highest prescription rate of generic statins coupled with a high disease burden.
  • Specialty generics are expected to grow moderately due to increasing investments and the focus of pharmaceutical companies to develop value-added products. In 2019, the U.S. FDA approved 110 complex generics.
  • Based on distribution channel, the retail pharmacy segment dominated the market space in 2022. Retail pharmacy chains across the world are investing in advanced technologies and undertaking new initiatives to improve sales and attract more customers.
  • North America held the majority share in 2022. Favorable government initiatives coupled with an evolving reimbursement landscape for pharmaceutical products support continual growth.
Product Code: GVR-4-68040-031-8

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market segmentation
    • 1.1.1 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity Flow Approach
      • 1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
  • 1.7 Global Market: CAGR Calculation
  • 1.8 Research Assumptions
  • 1.9 List of Secondary Sources
  • 1.10 List of Primary Sources
  • 1.11 Primary Research Analysis
    • 1.11.1 Market scenario
    • 1.11.2 Key KoL responses
  • 1.12 Objectives
    • 1.12.1 Objective 1:
    • 1.12.2 Objective 2:
  • 1.13 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Competitive Snapshoty

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Penetration and Growth Prospect Mapping
  • 3.2 Regulatory Landscape
  • 3.3 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
  • 3.4 Porter's Five Forces Analysis
  • 3.5 User Perspective Analysis
  • 3.6 Generic Pharmaceuticals Market Dynamics
    • 3.6.1 Market Driver Analysis
      • 3.6.1.1 Patent expiry of biologics and small molecules
      • 3.6.1.2 Increasing ANDA approval and Generic Product Launches
      • 3.6.1.3 Government initiatives to promote usage of generics
      • 3.6.1.4 Increasing Disease Burden and Rising Geriatric Population
    • 3.6.2 Market Restraint Analysis
      • 3.6.2.1 Pricing Pressures

Chapter 4 Generic Pharmaceuticals Market - Segment Analysis, By Type, 2018 - 2030 (USD Billion)

  • 4.1 Generic Pharmaceuticals Market: Type Movement Analysis
  • 4.2 Simple Generics
    • 4.2.1 Simple Generics Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 4.3 Specialty Generics
    • 4.3.1 Specialty Generics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.4 Biosimilars
    • 4.4.1 Biosimilars Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5 Generic Pharmaceuticals Market - Segment Analysis, By Application, 2018 - 2030 (USD Billion)

  • 5.1 Generic Pharmaceuticals Market: Application Movement Analysis
  • 5.2 Central Nervous System Disorders
    • 5.2.1 Central Nervous System Disorders Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.3 Respiratory Diseases
    • 5.3.1 Respiratory Diseases Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.4 Hormones and Related Diseases
    • 5.4.1 Hormones and Related Diseases Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.5 Gastrointestinal Diseases
    • 5.5.1 Gastrointestinal Diseases Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.6 Cardiovascular Diseases
    • 5.6.1 Cardiovascular Diseases Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.7 Infectious Diseases
    • 5.7.1 Infectious Diseases Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.8 Cancer
    • 5.8.1 Cancer Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.9 Diabetes
    • 5.9.1 Diabetes Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.10 Others
    • 5.10.1 Others Market Estimates and Forecast, 2018 - 2030 (USD Billion)

Chapter 6 Generic Pharmaceuticals Market - Segment Analysis, By Product, 2018 - 2030 (USD Billion)

  • 6.1 Generic Pharmaceuticals Market: Product Movement Analysis
  • 6.2 Small Molecule
    • 6.2.1 Small Molecule Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.3 Large Molecule
    • 6.3.1 Large molecule Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7 Generic Pharmaceuticals Market - Segment Analysis, By Route of Administration, 2018 - 2030 (USD Billion)

  • 7.1 Generic Pharmaceuticals Market: Route of Administration Movement Analysis
  • 7.2 Oral
    • 7.2.1 Oral Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 7.3 Injectable
    • 7.3.1 Injectable Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 7.4 Inhalable
    • 7.4.1 Inhalable Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 7.5 Others
    • 7.5.1 Others Market Estimates and Forecast, 2018 - 2030 (USD Billion)

Chapter 8 Generic Pharmaceuticals Market - Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Billion)

  • 8.1 Generic Pharmaceuticals Market: Distribution Channel Movement Analysis
  • 8.2 Hospital Pharmacy
    • 8.2.1 Hospital Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 8.3 Retail Pharmacy
    • 8.3.1 Retail Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 8.4 Online Pharmacy
    • 8.4.1 Online Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Billion)

Chapter 9 Generic Pharmaceuticals Market - Segment Analysis, By Region, 2018 - 2030 (USD Billion)

  • 9.1 Generic Pharmaceuticals Market, Market Share by Region, 2022 & 2030
  • 9.2 North America
    • 9.2.1 SWOT Analysis
      • 9.2.1.1 North America Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.2 U.S.
      • 9.2.2.1 Key Country Dynamics
      • 9.2.2.2 Target Disease Prevalence
      • 9.2.2.3 Competitive Scenario
      • 9.2.2.4 Regulatory Framework
      • 9.2.2.5 Reimbursement Scenario
      • 9.2.2.6 U.S. Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.3 Canada
      • 9.2.3.1 Key Country Dynamics
      • 9.2.3.2 Target Disease Prevalence
      • 9.2.3.3 Competitive Scenario
      • 9.2.3.4 Regulatory Framework
      • 9.2.3.5 Reimbursement Scenario
      • 9.2.3.6 Canada Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.2 Europe
    • 9.2.1 SWOT Analysis:
      • 9.2.1.1 Europe Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.2 Germany
      • 9.2.2.1 Key Country Dynamics
      • 9.2.2.2 Target Disease Prevalence
      • 9.2.2.3 Competitive Scenario
      • 9.2.2.4 Regulatory Framework
      • 9.2.2.5 Reimbursement Scenario
      • 9.2.2.6 Germany Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.3 U.K.
      • 9.2.3.1 Key Country Dynamics
      • 9.2.3.2 Target Disease Prevalence
      • 9.2.3.3 Competitive Scenario
      • 9.2.3.4 Regulatory Framework
      • 9.2.3.5 Reimbursement Scenario
      • 9.2.3.6 UK Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.4 France
      • 9.2.4.1 Key Country Dynamics
      • 9.2.4.2 Target Disease Prevalence
      • 9.2.4.3 Competitive Scenario
      • 9.2.4.4 Regulatory Framework
      • 9.2.4.5 Reimbursement Scenario
      • 9.2.4.6 France Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.5 Italy
      • 9.2.5.1 Key Country Dynamics
      • 9.2.5.2 Target Disease Prevalence
      • 9.2.5.3 Competitive Scenario
      • 9.2.5.4 Regulatory Framework
      • 9.2.5.5 Reimbursement Scenario
      • 9.2.5.6 Italy Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.6 Spain
      • 9.2.6.1 Key Country Dynamics
      • 9.2.6.2 Target Disease Prevalence
      • 9.2.6.3 Competitive Scenario
      • 9.2.6.4 Regulatory Framework
      • 9.2.6.5 Reimbursement Scenario
      • 9.2.6.6 Spain Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.7 Denmark
      • 9.2.7.1 Key Country Dynamics
      • 9.2.7.2 Target Disease Prevalence
      • 9.2.7.3 Competitive Scenario
      • 9.2.7.4 Regulatory Framework
      • 9.2.7.5 Reimbursement Scenario
      • 9.2.7.6 Denmark Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.8 Sweden
      • 9.2.8.1 Key Country Dynamics
      • 9.2.8.2 Target Disease Prevalence
      • 9.2.8.3 Competitive Scenario
      • 9.2.8.4 Regulatory Framework
      • 9.2.8.5 Reimbursement Scenario
      • 9.2.8.6 Sweden Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.9 Norway
      • 9.2.9.1 Key Country Dynamics
      • 9.2.9.2 Target Disease Prevalence
      • 9.2.9.3 Competitive Scenario
      • 9.2.9.4 Regulatory Framework
      • 9.2.9.5 Reimbursement Scenario
      • 9.2.9.6 Norway Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 9.2.9.7 Rest of Europe Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.3 Asia Pacific
    • 9.3.1 SWOT Analysis:
      • 9.3.1.1 Asia Pacific Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.3.2 Japan
      • 9.3.2.1 Key Country Dynamics
      • 9.3.2.2 Target Disease Prevalence
      • 9.3.2.3 Competitive Scenario
      • 9.3.2.4 Regulatory Framework
      • 9.3.2.5 Reimbursement Scenario
      • 9.3.2.6 Japan Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.3.3 China
      • 9.3.3.1 Key Country Dynamics
      • 9.3.3.2 Target Disease Prevalence
      • 9.3.3.3 Competitive Scenario
      • 9.3.3.4 Regulatory Framework
      • 9.3.3.5 Reimbursement Scenario
      • 9.3.3.6 China Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.3.4 India
      • 9.3.4.1 Key Country Dynamics
      • 9.3.4.2 Target Disease Prevalence
      • 9.3.4.3 Competitive Scenario
      • 9.3.4.4 Regulatory Framework
      • 9.3.4.5 Reimbursement Scenario
      • 9.3.4.6 India Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.3.5 Australia
      • 9.3.5.1 Key Country Dynamics
      • 9.3.5.2 Target Disease Prevalence
      • 9.3.5.3 Competitive Scenario
      • 9.3.5.4 Regulatory Framework & Reimbursement Scenario
      • 9.3.5.5 Australia Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.3.6 Thailand
      • 9.3.6.1 Key Country Dynamics
      • 9.3.6.2 Target Disease Prevalence
      • 9.3.6.3 Competitive Scenario
      • 9.3.6.4 Regulatory Framework & Reimbursement Scenario
      • 9.3.6.5 Thailand Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.3.7 South Korea
      • 9.3.7.1 Key Country Dynamics
      • 9.3.7.2 Target Disease Prevalence
      • 9.3.7.3 Competitive Scenario
      • 9.3.7.4 Regulatory Framework & Reimbursement Scenario
      • 9.3.7.5 South Korea Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 9.3.7.6 Rest of Asia Pacific Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.4 Latin America
    • 9.4.1 SWOT Analysis:
      • 9.4.1.1 Latin America Generic Pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 9.4.2 Brazil
      • 9.4.2.1 Key Country Dynamics
      • 9.4.2.2 Target Disease Prevalence
      • 9.4.2.3 Competitive Scenario
      • 9.4.2.4 Regulatory Framework
      • 9.4.2.5 Reimbursement Scenario
      • 9.4.2.6 Brazil Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.4.3 Mexico
      • 9.4.3.1 Key Country Dynamics
      • 9.4.3.2 Target Disease Prevalence
      • 9.4.3.3 Competitive Scenario
      • 9.4.3.4 Regulatory Framework
      • 9.4.3.5 Reimbursement Scenario
      • 9.4.3.6 Mexico Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.4.4 Argentina
      • 9.4.4.1 Key Country Dynamics
      • 9.4.4.2 Target Disease Prevalence
      • 9.4.4.3 Competitive Scenario
      • 9.4.4.4 Regulatory Framework
      • 9.4.4.5 Reimbursement Scenario
      • 9.4.4.6 Argentina Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 9.4.4.7 Rest of Latin America Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5 Middle East & Africa (MEA)
    • 9.5.1 SWOT Analysis:
      • 9.5.1.1 Middle East & Africa Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.2 South Africa
      • 9.5.2.1 Key Country Dynamics
      • 9.5.2.2 Target Disease Prevalence
      • 9.5.2.3 Competitive Scenario
      • 9.5.2.4 Regulatory Framework
      • 9.5.2.5 Reimbursement Scenario
      • 9.5.2.6 South Africa Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.3 Saudi Arabia
      • 9.5.3.1 Key Country Dynamics
      • 9.5.3.2 Target Disease Prevalence
      • 9.5.3.3 Competitive Scenario
      • 9.5.3.4 Regulatory Framework
      • 9.5.3.5 Reimbursement Scenario
      • 9.5.3.6 Saudi Arabia Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.4 UAE
      • 9.5.4.1 Key Country Dynamics
      • 9.5.4.2 Target Disease Prevalence
      • 9.5.4.3 Competitive Scenario
      • 9.5.4.4 Regulatory Framework
      • 9.5.4.5 Reimbursement Scenario
      • 9.5.4.6 UAE Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.5 Kuwait
      • 9.5.5.1 Key Country Dynamics
      • 9.5.5.2 Target Disease Prevalence
      • 9.5.5.3 Competitive Scenario
      • 9.5.5.4 Regulatory Framework
      • 9.5.5.5 Reimbursement Scenario
      • 9.5.5.6 Kuwait Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 9.5.5.7 Rest of MEA Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 10 Generic Pharmaceuticals Market - Competitive Analysis

  • 10.1 Recent Developments & Impact Analysis, by Key Market Participants
    • 10.1.1 New Product Launch
    • 10.1.2 Merger and Acquisition
    • 10.1.3 Licensing Agreements
    • 10.1.4 Conferences and Campaigns
  • 10.2 Company Categorization
    • 10.2.1 Innovators
    • 10.2.2 Market Leaders
  • 10.3 Vendor Landscape
    • 10.3.1 List of key distributors and channel partners
    • 10.3.2 Key customers
  • 10.4 Public Companies
    • 10.4.1 Key company market share analysis, 2022
    • 10.4.2 Company market position analysis
    • 10.4.3 Heat map analysis
    • 10.4.4 Competitive Dashboard Analysis
      • 10.4.4.1 Market Differentiators
  • 10.5 Private Companies
    • 10.5.1 List of key emerging companies
    • 10.5.2 Regional Network Map
  • 10.6 Company Profile
    • 10.6.1 Teva Pharmaceutical Industries Ltd
      • 10.6.1.1 Company overview
      • 10.6.1.2 Financial performance
      • 10.6.1.3 Product benchmarking
      • 10.6.1.4 Strategic initiatives
    • 10.6.2 Viatris Inc.)
      • 10.6.2.1 Company overview
      • 10.6.2.2 Financial performance
      • 10.6.2.3 Product benchmarking
      • 10.6.2.4 Strategic initiatives
    • 10.6.3 Sun Pharmaceutical Industries Ltd.
      • 10.6.3.1 Company overview
      • 10.6.3.2 Financial performance
      • 10.6.3.3 Product benchmarking
      • 10.6.3.4 Strategic initiatives
    • 10.6.4 LUPIN
      • 10.6.4.1 Company overview
      • 10.6.4.2 Financial performance
      • 10.6.4.3 Product benchmarking
      • 10.6.4.4 Strategic initiatives
    • 10.6.5 Novartis AG
      • 10.6.5.1 Company overview
      • 10.6.5.2 Sandoz International GmbH
      • 10.6.5.3 Financial performance
      • 10.6.5.4 Product benchmarking
      • 10.6.5.5 Strategic initiatives
    • 10.6.6 Allergan
      • 10.6.6.1 Company overview
      • 10.6.6.2 Financial performance
      • 10.6.6.3 Product benchmarking
      • 10.6.6.4 Strategic initiatives
    • 10.6.7 AstraZeneca
      • 10.6.7.1 Company overview
      • 10.6.7.2 Financial performance
      • 10.6.7.3 Product benchmarking
      • 10.6.7.4 Strategic initiatives
    • 10.6.8 Sawai Pharmaceutical Co., Ltd.
      • 10.6.8.1 Company overview
      • 10.6.8.2 Financial performance
      • 10.6.8.3 Product benchmarking
      • 10.6.8.4 Strategic initiatives
    • 10.6.9 Hikma Pharmaceuticals PLC
      • 10.6.9.1 Company overview
      • 10.6.9.2 Financial performance
      • 10.6.9.3 Product benchmarking
      • 10.6.9.4 Strategic initiatives
    • 10.6.10 Dr. Reddy's Laboratories Ltd.
      • 10.6.10.1 Company overview
      • 10.6.10.2 Financial performance
      • 10.6.10.3 Product benchmarking
      • 10.6.10.4 Strategic initiatives
    • 10.6.11 Cipla Inc.
      • 10.6.11.1 Company overview
      • 10.6.11.2 Financial performance
      • 10.6.11.3 Product benchmarking
      • 10.6.11.4 Strategic initiatives
    • 10.6.12 Sanofi
      • 10.6.12.1 Company overview
      • 10.6.12.2 Financial performance
      • 10.6.12.3 Product benchmarking
      • 10.6.12.4 Strategic initiatives
    • 10.6.13 Aurobindo Pharma
      • 10.6.13.1 Company overview
      • 10.6.13.2 Financial performance
      • 10.6.13.3 Product benchmarking
      • 10.6.13.4 Strategic initiatives
    • 10.6.14 Endo International plc
      • 10.6.14.1 Company overview
      • 10.6.14.2 Financial performance
      • 10.6.14.3 Product benchmarking
      • 10.6.14.4 Strategic initiatives
Product Code: GVR-4-68040-031-8

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviation
  • Table 3 Regulatory framework
  • Table 4 Patent expiry
  • Table 5 First generic products
  • Table 6 Healthcare expenses on pharmaceuticals
  • Table 7 Complex generic approved by U.S.FDA (2019)
  • Table 8 Prevalence of GERD
  • Table 9 Estimated new cancer case statistics, 2022
  • Table 10 Total Glaucoma Cases (2020)
  • Table 11 First generic oral products approved in 2019
  • Table 12 Leading market players anticipated to witness highest growth
  • Table 13 List of key distributor
  • Table 14 North America Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 15 North America Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 16 North America Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 17 North America Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 18 North America Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 19 U.S. Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 20 U.S. Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 21 U.S. Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 22 U.S. Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 23 U.S. Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 24 Canada Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 25 Canada Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 26 Canada Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 26 Canada Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 27 Canada Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 28 Europe Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 29 Europe Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 29 Europe Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 30 Europe Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 31 Europe Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 32 U.K. Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 33 U.K. Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 34 U.K. Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 35 U.K. Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 36 U.K. Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 37 Germany Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 38 Germany Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 39 Germany Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 40 Germany Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 41 Germany Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 42 Italy Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 43 Italy Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 44 Italy Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 45 Italy Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 46 Italy Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 47 France Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 48 France Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 49 France Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 50 France Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 51 France Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 52 Spain Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 53 Spain Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 54 Spain Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 55 Spain Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 56 Spain Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 57 Denmark Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 58 Denmark Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 59 Denmark Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 60 Denmark Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 61 Denmark Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 62 Sweden Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 63 Sweden Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 64 Sweden Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 65 Sweden Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 66 Sweden Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 67 Norway Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 68 Norway Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 69 Norway Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 70 Norway Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 71 Norway Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 72 Asia Pacific Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 73 Asia Pacific Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 74 Asia Pacific Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 75 Asia Pacific Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 76 Asia Pacific Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 77 Japan Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 78 Japan Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 79 Japan Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 80 Japan Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 81 Japan Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 82 China Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 83 China Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 84 China Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 85 China Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 86 China Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 87 India Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 88 India Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 89 India Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 90 India Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 91 India Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 92 Australia Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 93 Australia Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 94 Australia Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 95 Australia Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 96 Australia Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 97 South Korea Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 98 South Korea Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 99 South Korea Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 100 South Korea Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 101 South Korea Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 102 Thailand Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 103 Thailand Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 104 Thailand Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 105 Thailand Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 106 Thailand Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 107 Latin America Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 108 Latin America Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 109 Latin America Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 110 Latin America Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 111 Latin America Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 112 Brazil Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 113 Brazil Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 114 Brazil Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 115 Brazil Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 116 Brazil Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 117 Mexico Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 118 Mexico Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 119 Mexico Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 120 Mexico Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 121 Mexico Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 122 Argentina Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 123 Argentina Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 124 Argentina Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 125 Argentina Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 126 Argentina Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 127 MEA Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 128 MEA Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 129 MEA Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 130 MEA Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 131 MEA Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 132 South Africa Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 133 South Africa Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 134 South Africa Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 135 South Africa Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 136 South Africa Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 137 Saudi Arabia Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 138 Saudi Arabia Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 139 Saudi Arabia Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 140 Saudi Arabia Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 141 Saudi Arabia Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 142 UAE Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 143 UAE Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 144 UAE Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 145 UAE Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 146 UAE Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 147 KUWAIT Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 148 KUWAIT Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 149 KUWAIT Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 150 KUWAIT Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 151 KUWAIT Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Generic Pharmaceuticals market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Commodity Flow Analysis
  • Fig. 10 Generic Pharmaceuticals Market Snapshot
  • Fig. 11 Penetration and growth prospect mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 User Perspective Analysis
  • Fig. 15 Generic Pharmaceuticals Market Driver Impact
  • Fig. 16 Disease burden of non-communicable diseases (in Million), in 2018
  • Fig. 17 Generic Pharmaceuticals Market Restraint Impact
  • Fig. 18 Generic Pharmaceuticals market: Type outlook and key takeaways
  • Fig. 19 Generic Pharmaceuticals market: Type movement analysis
  • Fig. 20 Simple generics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 21 Specialty generics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 22 Biosimilars Market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 23 Generic Pharmaceuticals market: Application outlook and key takeaways
  • Fig. 24 Generic Pharmaceuticals market: Application movement analysis
  • Fig. 25 Central nervous system disorders market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 26 Respiratory diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 27 Hormones and related diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 28 Gastrointestinal diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 29 Cardiovascular diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 30 Infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 31 Cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 32 Diabetes market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 34 Generic Pharmaceuticals market: Product outlook and key takeaways
  • Fig. 35 Generic Pharmaceuticals market: Product movement analysis
  • Fig. 36 Small molecule market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 37 Large molecule market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 38 Generic Pharmaceuticals Market: Route of Administration Outlook and Key Takeaways
  • Fig. 39 Generic Pharmaceuticals market: Route of administration movement analysis
  • Fig. 40 Oral market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 41 Injectable market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 42 Inhalable market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 43 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 44 Generic Pharmaceuticals Market: Distribution Channel Outlook and Key Takeaways
  • Fig. 45 Generic Pharmaceuticals Market: Distribution Channel Movement Analysis
  • Fig. 46 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 47 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 48 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 49 Regional marketplace: Key takeaways
  • Fig. 50 Regional outlook, 2020 & 2030
  • Fig. 51 North America
  • Fig. 52 North America. market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 53 U.S.
  • Fig. 54 U.S. market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 55 Canada
  • Fig. 56 Canada market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 57 Europe
  • Fig. 58 Europe market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 59 U.K.
  • Fig. 60 U.K. market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 61 Germany
  • Fig. 62 Germany market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 63 France
  • Fig. 64 France market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 65 Spain
  • Fig. 66 Spain market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 67 Italy
  • Fig. 68 Italy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 69 Denmark
  • Fig. 70 Denmark market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 71 Sweden
  • Fig. 72 Sweden market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 73 Norway
  • Fig. 74 Norway market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 75 Asia-Pacific
  • Fig. 76 Asia-Pacific market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 77 Japan
  • Fig. 78 Japan market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 79 China
  • Fig. 80 China market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 81 India
  • Fig. 82 India market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 83 Australia
  • Fig. 84 Australia market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 85 South Korea
  • Fig. 86 South Korea market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 87 Thailand
  • Fig. 88 Thailand market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 89 Latin America
  • Fig. 90 Latin America market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 91 Brazil
  • Fig. 92 Brazil market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 93 Mexico
  • Fig. 94 Mexico market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 95 Argentina
  • Fig. 96 Argentina market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 97 Middle East & Africa
  • Fig. 98 MEA market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 99 South Africa
  • Fig. 100 South Africa market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 101 Saudi Arabia
  • Fig. 102 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 103 UAE
  • Fig. 104 UAE market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 105 Kuwait
  • Fig. 106 Kuwait market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 107 Market position analysis
  • Fig. 108 Profit margin
  • Fig. 109 Heat map analysis
  • Fig. 110 Market differentiators
  • Fig. 111 Regional Network Map
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!